Kyverna Therapeutics, Inc. (KYTX) Tops Q2 EPS by 5c

Kyverna Therapeutics, Inc. (NASDAQ: KYTX) reported Q2 EPS of ($0.97), $0.05 better than the analyst estimate of ($1.02).

For earnings history and earnings-related data on Kyverna Therapeutics, Inc. (KYTX) click here.

You May Also Be Interested In

• Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c
• Grocery Outlet Holding (GO) PT Raised to $11.50 at UBS